MedTrace Logo

Potassium Supplementation in CKD

NCT03253172 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 532

Last updated 2026-02-12

No results posted yet for this study

Summary

The current high-sodium, low-potassium diet contributes to the high prevalence of high blood pressure (hypertension). Indeed, the anti-hypertensive effects of potassium supplementation are well-established. Hypertension is even more prevalent and resistant in patients with chronic kidney disease (CKD) and contributes to further decline in kidney function. Four recent epidemiological studies (published 2014 - 2016) showed that higher dietary potassium intake was associated with better renal outcomes. All studies recommended an intervention study with potassium supplementation in patients with CKD, but this has not been performed. The aim of this study is to study the renoprotective effect of potassium supplementation in patients with CKD (stage 3b or 4, i.e. estimated glomerular filtration rate \[eGFR\] 15 - 45 ml/min/1.73 m2).

Conditions

  • Renal Insufficiency, Chronic
  • Potassium Depletion
  • Hypertension
  • Hyperkalemia

Interventions

DIETARY_SUPPLEMENT

Potassium Chloride

Two potassium supplements with varying anions.

DIETARY_SUPPLEMENT

Potassium Citrate

Potassium Citrate

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Dutch Kidney Foundation

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • Amsterdam UMC

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Ewout J Hoorn, MD, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2026-05-01
Completion
2026-10-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253172 on ClinicalTrials.gov